SURGERY PARTNERS INC (SGRY) Fundamental Analysis & Valuation

NASDAQ:SGRY • US86881A1007

Current stock price

14.49 USD
-0.05 (-0.34%)
Last:

This SGRY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. SGRY Profitability Analysis

1.1 Basic Checks

  • In the past year SGRY was profitable.
  • In the past year SGRY had a positive cash flow from operations.
  • In the past 5 years SGRY always reported negative net income.
  • Each year in the past 5 years SGRY had a positive operating cash flow.
SGRY Yearly Net Income VS EBIT VS OCF VS FCFSGRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • SGRY has a Return On Assets of -0.96%. This is comparable to the rest of the industry: SGRY outperforms 42.00% of its industry peers.
  • With a Return On Equity value of -4.55%, SGRY perfoms like the industry average, outperforming 47.00% of the companies in the same industry.
  • SGRY has a Return On Invested Capital (5.05%) which is in line with its industry peers.
  • SGRY had an Average Return On Invested Capital over the past 3 years of 5.12%. This is below the industry average of 8.40%.
Industry RankSector Rank
ROA -0.96%
ROE -4.55%
ROIC 5.05%
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
SGRY Yearly ROA, ROE, ROICSGRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

1.3 Margins

  • With an excellent Operating Margin value of 14.49%, SGRY belongs to the best of the industry, outperforming 89.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of SGRY has grown nicely.
  • Looking at the Gross Margin, with a value of 25.78%, SGRY is in line with its industry, outperforming 55.00% of the companies in the same industry.
  • SGRY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.49%
PM (TTM) N/A
GM 25.78%
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
SGRY Yearly Profit, Operating, Gross MarginsSGRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. SGRY Health Analysis

2.1 Basic Checks

  • SGRY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, SGRY has more shares outstanding
  • SGRY has more shares outstanding than it did 5 years ago.
  • SGRY has a worse debt/assets ratio than last year.
SGRY Yearly Shares OutstandingSGRY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
SGRY Yearly Total Debt VS Total AssetsSGRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • SGRY has an Altman-Z score of 0.72. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 0.72, SGRY is not doing good in the industry: 71.00% of the companies in the same industry are doing better.
  • The Debt to FCF ratio of SGRY is 18.93, which is on the high side as it means it would take SGRY, 18.93 years of fcf income to pay off all of its debts.
  • With a Debt to FCF ratio value of 18.93, SGRY is not doing good in the industry: 65.00% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 2.10 is on the high side and indicates that SGRY has dependencies on debt financing.
  • The Debt to Equity ratio of SGRY (2.10) is worse than 74.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.1
Debt/FCF 18.93
Altman-Z 0.72
ROIC/WACC0.55
WACC9.16%
SGRY Yearly LT Debt VS Equity VS FCFSGRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.87 indicates that SGRY should not have too much problems paying its short term obligations.
  • SGRY's Current ratio of 1.87 is fine compared to the rest of the industry. SGRY outperforms 78.00% of its industry peers.
  • A Quick Ratio of 1.71 indicates that SGRY should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.71, SGRY is in the better half of the industry, outperforming 74.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.87
Quick Ratio 1.71
SGRY Yearly Current Assets VS Current LiabilitesSGRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SGRY Growth Analysis

3.1 Past

  • The earnings per share for SGRY have decreased strongly by -51.06% in the last year.
  • The Earnings Per Share has been growing by 52.38% on average over the past years. This is a very strong growth
  • SGRY shows a small growth in Revenue. In the last year, the Revenue has grown by 6.24%.
  • The Revenue has been growing by 12.21% on average over the past years. This is quite good.
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%

3.2 Future

  • Based on estimates for the next years, SGRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.17% on average per year.
  • The Revenue is expected to grow by 8.28% on average over the next years. This is quite good.
EPS Next Y-46.78%
EPS Next 2Y-0.67%
EPS Next 3Y12.18%
EPS Next 5Y17.17%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.28%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SGRY Yearly Revenue VS EstimatesSGRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B
SGRY Yearly EPS VS EstimatesSGRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. SGRY Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 31.50 indicates a quite expensive valuation of SGRY.
  • SGRY's Price/Earnings ratio is in line with the industry average.
  • SGRY's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.15.
  • The Price/Forward Earnings ratio is 59.19, which means the current valuation is very expensive for SGRY.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SGRY is on the same level as its industry peers.
  • SGRY's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.12.
Industry RankSector Rank
PE 31.5
Fwd PE 59.19
SGRY Price Earnings VS Forward Price EarningsSGRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SGRY is valued a bit cheaper than the industry average as 80.00% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, SGRY is valued cheaply inside the industry as 84.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.59
EV/EBITDA 8.15
SGRY Per share dataSGRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SGRY's earnings are expected to grow with 12.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.67%
EPS Next 3Y12.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SGRY Dividend Analysis

5.1 Amount

  • SGRY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SGRY Fundamentals: All Metrics, Ratios and Statistics

SURGERY PARTNERS INC

NASDAQ:SGRY (4/28/2026, 12:11:54 PM)

14.49

-0.05 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-02
Earnings (Next)05-05
Inst Owners83.54%
Inst Owner Change-0.32%
Ins Owners1.63%
Ins Owner Change1.19%
Market Cap1.88B
Revenue(TTM)3.31B
Net Income(TTM)-77.90M
Analysts81.11
Price Target19.66 (35.68%)
Short Float %20.58%
Short Ratio10.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.91%
Min EPS beat(2)-60.78%
Max EPS beat(2)-23.03%
EPS beat(4)1
Avg EPS beat(4)-21%
Min EPS beat(4)-60.78%
Max EPS beat(4)24.15%
EPS beat(8)4
Avg EPS beat(8)-6.88%
EPS beat(12)8
Avg EPS beat(12)176.88%
EPS beat(16)9
Avg EPS beat(16)102.65%
Revenue beat(2)1
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)0.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.14%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)4
Avg Revenue beat(12)-0.76%
Revenue beat(16)6
Avg Revenue beat(16)-0.79%
PT rev (1m)-24.28%
PT rev (3m)-25.87%
EPS NQ rev (1m)2.69%
EPS NQ rev (3m)-519.28%
EPS NY rev (1m)-67.35%
EPS NY rev (3m)-67.35%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)-2.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.21%
Valuation
Industry RankSector Rank
PE 31.5
Fwd PE 59.19
P/S 0.57
P/FCF 9.59
P/OCF 6.84
P/B 1.09
P/tB N/A
EV/EBITDA 8.15
EPS(TTM)0.46
EY3.17%
EPS(NY)0.24
Fwd EY1.69%
FCF(TTM)1.51
FCFY10.43%
OCF(TTM)2.12
OCFY14.63%
SpS25.57
BVpS13.24
TBVpS-27.22
PEG (NY)N/A
PEG (5Y)N/A
Graham Number11.704 (-19.23%)
Profitability
Industry RankSector Rank
ROA -0.96%
ROE -4.55%
ROCE 6.39%
ROIC 5.05%
ROICexc 5.21%
ROICexgc 18.67%
OM 14.49%
PM (TTM) N/A
GM 25.78%
FCFM 5.91%
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
ROICexc(3y)5.3%
ROICexc(5y)5.11%
ROICexgc(3y)19.01%
ROICexgc(5y)18.72%
ROCE(3y)6.48%
ROCE(5y)6.19%
ROICexgc growth 3Y2.9%
ROICexgc growth 5Y5.08%
ROICexc growth 3Y1.35%
ROICexc growth 5Y9.67%
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
F-Score5
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 2.1
Debt/FCF 18.93
Debt/EBITDA 5.5
Cap/Depr 44.72%
Cap/Sales 2.38%
Interest Coverage 1.87
Cash Conversion 41.85%
Profit Quality N/A
Current Ratio 1.87
Quick Ratio 1.71
Altman-Z 0.72
F-Score5
WACC9.16%
ROIC/WACC0.55
Cap/Depr(3y)59.72%
Cap/Depr(5y)61.53%
Cap/Sales(3y)2.84%
Cap/Sales(5y)2.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y-46.78%
EPS Next 2Y-0.67%
EPS Next 3Y12.18%
EPS Next 5Y17.17%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.28%
EBIT growth 1Y1.03%
EBIT growth 3Y8.59%
EBIT growth 5Y20.49%
EBIT Next Year28.56%
EBIT Next 3Y15.28%
EBIT Next 5YN/A
FCF growth 1Y-6.72%
FCF growth 3Y35.74%
FCF growth 5Y-0.84%
OCF growth 1Y-8.6%
OCF growth 3Y19.98%
OCF growth 5Y2.13%

SURGERY PARTNERS INC / SGRY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SGRY.


What is the valuation status for SGRY stock?

ChartMill assigns a valuation rating of 3 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Overvalued.


Can you provide the profitability details for SURGERY PARTNERS INC?

SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.


What is the valuation of SURGERY PARTNERS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 31.5 and the Price/Book (PB) ratio is 1.09.


Can you provide the expected EPS growth for SGRY stock?

The Earnings per Share (EPS) of SURGERY PARTNERS INC (SGRY) is expected to decline by -46.78% in the next year.